Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1556/650.2021.HO2689 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A surrogate ELISA to select high titer human convalescent plasma for treating immunocompromised patients infected with SARS-CoV-2 variants of concern.
J Infect Dis
January 2025
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Background: The emergence of new SARS-CoV-2 variants poses a new challenge for the treatment of immunocompromised patients against COVID-19. In this context, high titer COVID-19 Convalescent Plasma (CCP) is one of the few available therapeutics for these patients. We have revisited the selection of CCP samples and its efficacy against Omicron XBB.
View Article and Find Full Text PDFTargets of influenza human T-cell response are mostly conserved in H5N1.
mBio
December 2024
Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, California, USA.
Frequent recent spillovers of subtype H5N1 clade 2.3.4.
View Article and Find Full Text PDF"Enriching the Hospital's Scientific Fame": Research at the Vienna Foundling Hospital.
Neonatology
December 2024
Background: Little is known about medical research at the Vienna Foundling Hospital during the 18th and 19th centuries.
Summary: The present paper focuses on nutrition, medical care, and research concerning newborn infants. In 1784, Emperor Joseph II merged obstetric and foundling hospitals under common leadership with specific statutes.
A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge.
Vaccine
December 2024
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:
The rapid development of coronavirus disease 2019 (COVID-19) vaccines has helped mitigate the initial impact of the pandemic. However, in order to reduce transmission rates and protect more vulnerable and immunocompromised individuals unable to mount an effective immune response, development of a next-generation of mucosal vaccines is necessary. Here, we developed an intranasal Newcastle disease virus (NDV)-based vaccine expressing the spike of the XBB.
View Article and Find Full Text PDFTick-Borne Encephalitis Virus Surveillance-Vaccination- and Infection-Induced Seroprevalences in Western Austria 2024.
J Med Virol
December 2024
Central Medical Laboratories, Feldkirch, Austria.
Reported tick-borne-encephalitis (TBE) cases have been increasing in Western Austria, but no data are available on vaccination- and infection-specific seroprevalence. This study aimed to estimate current TBEV-seroprevalence in the region and inform prevention programs by comparing anti-NS1-based-incidence rates with reported case numbers and vaccination coverage. Between December 2023 and February 2024, serum samples from 4619 blood donors in Western Austria were collected and analyzed using TBEV- and WNV-IgG-ELISA assays.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!